Tamoxifen Resistance in Breast Tumors Is Driven by Growth Factor Receptor Signaling with Repression of Classic Estrogen Receptor Genomic FunctionSuleiman Massarweh, Rachel Schiff, C. Kent Osborne et al.|Cancer Research|2008Cited by 494
Insulin-Like Growth Factor-I Activates Gene Transcription Programs Strongly Associated With Poor Breast Cancer PrognosisChad J. Creighton, Adrian V. Lee, Angelo Casà et al.|Journal of Clinical Oncology|2008Cited by 261
Randomized Phase II Study Evaluating Palbociclib in Addition to Letrozole as Neoadjuvant Therapy in Estrogen Receptor–Positive Early Breast Cancer: PALLET TrialStephen Johnston, Samuel A. Jacobs, Shannon Puhalla et al.|Journal of Clinical Oncology|2018Cited by 233
An epigenomic approach to therapy for tamoxifen-resistant breast cancerQin Feng, Bert W. O’Malley, Zheng Zhang et al.|Cell Research|2014Cited by 188
FOXA1 overexpression mediates endocrine resistance by altering the ER transcriptome and IL-8 expression in ER-positive breast cancerXiaoyong Fu, Rachel Schiff, Rinath Jeselsohn et al.|Proceedings of the National Academy of Sciences|2016Cited by 185